Nokea
A nurse is reading a journal article about seasonal allergies and comes across the name of the drug loratadine. The nurse identifies this drug name as which of the following?
- A. Chemical
- B. Generic
- C. Trade
- D. Brand
Correct Answer: B
Rationale: The generic name is the name given to a drug that can be made or marketed by any company and is the name given to the drug by the FDA. The chemical name is the scientific term that describes the molecular structure of the drugs, typically the chemical components. The trade or brand name of the drug is the name selected by a specific company for marketing purposes and is followed by a trademark symbol or registered trademark symbol.
You may also like to solve these questions
When reviewing the phases of drug development, the nurse finds a discussion about the postmarketing surveillance phase. Which one of the following activities would the nurse expect to find as being carried out during this phase?
- A. Health care providers report adverse effects to FDA.
- B. Healthy volunteers are involved in the test.
- C. In vitro tests are performed using human cells.
- D. The drug is given to patients with the disease.
Correct Answer: A
Rationale: The postmarketing surveillance phase of drug development encourages health care professionals to report adverse effects of drugs to the FDA using MedWatch. Phase 1 of clinical testing involves 20 to 100 healthy volunteers. In vitro testing of the drug on human or animal cells is done in the pre-FDA phase. In Phase 2 of clinical testing, the drug is given to patients with the disease for which the drug is manufactured.
A nurse is preparing a teaching plan for a client who is prescribed an oral medication. As part of the plan, the nurse expects to describe the importance of absorption. The nurse would integrate knowledge of which of the following as a mechanism for absorption in the gastrointestinal tract? Select all that apply.
- A. Active transport
- B. Transposition
- C. Passive transport
- D. Endocytosis
- E. Pinocytosis
Correct Answer: A,C,E
Rationale: During absorption, the drug particles in the GI tract are moved into the body fluids via active transport, passive transport, and pinocytosis.
A group of nursing students are reviewing information about drug development in the United States in preparation for an exam. The students demonstrate understanding of this material when they identify testing of which of the following as one of the first steps?
- A. Small group of healthy volunteers
- B. People who have the disease
- C. Live animals
- D. Large numbers of patients
Correct Answer: C
Rationale: Initially, drug testing begins with testing in an artificial environment such as a test tube, and then this testing is followed by testing on live animals. Next, clinical testing occurs with each phase involving a larger number of people. First, a small group of 20 to 100 healthy volunteers are tested; then testing is performed on people who have the disease or condition. Last, the drug is given to large numbers of patients in medical research centers.
A patient is receiving digoxin as treatment for heart failure. Which of the following would be most important for the nurse to monitor to reduce the risk for toxicity?
- A. Seizure activity
- B. Drug blood level
- C. Urinary output
- D. Blood pressure
Correct Answer: B
Rationale: The nurse should monitor the patient's blood level of the drug to ensure that the level remains within the therapeutic range. Monitoring seizure activity, urination frequency, and blood pressure will not prevent toxicity. Seizure activity is unrelated to digoxin or heart failure.
Which of the following is true regarding the Dietary Supplement Health and Education Act (DSHEA)? Select all that apply.
- A. The act allows for DEA enforcement of the act.
- B. The act gives the FDA power to enforce the laws governed by the act.
- C. The act permits general health claims.
- D. The act permits curative health claims.
- E. The act defines specific substances as 'dietary supplements.'
Correct Answer: B,C,E
Rationale: The DSHEA defines substances such as herbs, vitamins, minerals, amino acids, and other natural substances as 'dietary supplements' and permits general health claims as long as the label also has a disclaimer stating that the supplements are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. The act gives the FDA the power to enforce the laws governed by the act.